Related references
Note: Only part of the references are listed.Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling
Hajira Bilal et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update
Emily N. Drwiega et al.
CLINICAL PHARMACOKINETICS (2022)
Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis
Sara Cortes-Lara et al.
CLINICAL MICROBIOLOGY AND INFECTION (2021)
Emergence of Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in Pseudomonas aeruginosa Sequence Type 308
Pablo A. Fraile-Ribot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
In pursuit of the triple crown: mechanism-based pharmacodynamic modelling for the optimization of three-drug combinations against KPC-producing Klebsiella pneumoniae
N. J. Onufrak et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data
Silvia Garazzino et al.
FRONTIERS IN PEDIATRICS (2020)
Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis
Antonio C. Arrieta et al.
PEDIATRIC PULMONOLOGY (2020)
Ceftolozane/tazobactam for pulmonary exacerbation in a 63-year-old cystic fibrosis patient with renal insufficiency and an elevated MIC to Pseudomonas aeruginosa
Meredith Tate Romano et al.
IDCASES (2020)
Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model
Joan Gomez-Junyent et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis
Sarah Elizabeth Davis et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2019)
Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated lntra-abdominal Infections
Kajal B. Larson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Tolerance and Resistance of Pseudomonas aeruginosa Biofilms to Antimicrobial Agents-How P. aeruginosa Can Escape Antibiotics
Oana Ciofu et al.
FRONTIERS IN MICROBIOLOGY (2019)
Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections
Juan P. Horcajada et al.
CLINICAL MICROBIOLOGY REVIEWS (2019)
Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model
Hajira Bilal et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa
Pablo A. Fraile-Ribot et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model
Veronica Rico Caballero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling
Rajbharan Yadav et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection
Alan R. Noel et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
ECFS best practice guidelines: the 2018 revision
Carlo Castellani et al.
JOURNAL OF CYSTIC FIBROSIS (2018)
The Versatile Mutational Resistome of Pseudomonas aeruginosa
Carla Lopez-Causape et al.
FRONTIERS IN MICROBIOLOGY (2018)
Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis
S. Stefani et al.
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY (2017)
Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone
Carla Lopez-Causape et al.
SCIENTIFIC REPORTS (2017)
Time-Kill Analysis of Ceftolozane/Tazobactam Efficacy Against Mucoid Pseudomonas aeruginosa Strains from Cystic Fibrosis Patients
Hana Rac et al.
INFECTIOUS DISEASES AND THERAPY (2017)
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance
Ghady Haidar et al.
CLINICAL INFECTIOUS DISEASES (2017)
In vitro Activity of Ceftolozane/Tazobactam Alone or with an Aminoglycoside Against Multi-Drug-Resistant Pseudomonas aeruginosa from Pediatric Cystic Fibrosis Patients
Aimee M. Dassner et al.
INFECTIOUS DISEASES AND THERAPY (2017)
Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection
Alasdair P. MacGowan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections
Estrella Rojo-Molinero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies
Gauri G. Rao et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
CpxR Activates MexAB-OprM Efflux Pump Expression and Enhances Antibiotic Resistance in Both Laboratory and Clinical nalB-Type Isolates of Pseudomonas aeruginosa
Zhe-Xian Tian et al.
PLOS PATHOGENS (2016)
Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC
Gabriel Cabot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model
Jaime Lora-Tamayo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis
Sanja Stanojevic et al.
JOURNAL OF CYSTIC FIBROSIS (2014)
Pseudomonas aeruginosa Diversification during Infection Development in Cystic Fibrosis Lungs-A Review
Ana Margarida Sousa et al.
PATHOGENS (2014)
Population Pharmacokinetics of Tobramycin in Patients With and Without Cystic Fibrosis
Stefanie Hennig et al.
CLINICAL PHARMACOKINETICS (2013)
Sputum Tobramycin Concentrations in Cystic Fibrosis Patients with Repeated Administration of Inhaled Tobramycin
Jennifer Ruddy et al.
JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY (2013)
Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis
M. Proesmans et al.
JOURNAL OF CYSTIC FIBROSIS (2013)
Clonal Dissemination, Emergence of Mutator Lineages and Antibiotic Resistance Evolution in Pseudomonas aeruginosa Cystic Fibrosis Chronic Lung Infection
Carla Lopez-Causape et al.
PLOS ONE (2013)
Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects
Gurudatt Chandorkar et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Overexpression of AmpC and Efflux Pumps in Pseudomonas aeruginosa Isolates from Bloodstream Infections: Prevalence and Impact on Resistance in a Spanish Multicenter Study
Gabriel Cabot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid Focus on Antibacterial Agents
Keith A. Rodvold et al.
CLINICAL PHARMACOKINETICS (2011)
Evolution and Adaptation in Pseudomonas aeruginosa Biofilms Driven by Mismatch Repair System-Deficient Mutators
Adela M. Lujan et al.
PLOS ONE (2011)
Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1
Elena Riera et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Cystic Fibrosis Pulmonary Guidelines Treatment of Pulmonary Exacerbations
Patrick A. Flume et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomised controlled trial
A Smyth et al.
LANCET (2005)
Aminoglycoside resistance in Pseudomonas aeruginosa
K Poole
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis
RL Gibson et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis
M Rosenfeld et al.
JOURNAL OF PEDIATRICS (2001)
High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection
A Oliver et al.
SCIENCE (2000)
Share Paper
